The novel aldosterone inhibitor works, but longer-term safety data are needed before the drug might be approved.

The choice between ICD types still should be based on each individual patient’s risk factors, Kenneth Ellenbogen says.

The US guidelines are likely to change following the release of the VANISH2 results last year, Christine Albert anticipates.

It’s no surprise that complications can vex concomitant procedures. But when staged, should PCI or TAVI come first?

The benefit of GLP-1 therapy couldn’t be explained by weight loss, suggesting that some pleiotropic effects may be at work.

Complications weren’t more common when leads were extracted. Yet there’s also the option of “jailing” leads instead.

Especially given its impact on cardiology, the WHI should be the “pride” of the US, not on the chopping block, says Martha ...

The novel dissolvable therapy had a 93.2% probability of being cost-effective at a modest willingness-to-pay level.

Ten years after learning their polygenic risk score, patients had fewer events—perhaps due to greater use of statin therapy.

SGLT2 inhibitors and GLP-1 agonists are class 1 medications, but many Medicaid patients have challenges with access.

Where this device will fit in with other emerging options remains to be seen, but it might hold an advantage in large annuli.

Limus-based devices, rather than being a substitute for paclitaxel as they were once seen, are coming of age in peripheral ...